Daily Stock Analysis, CSBR, Champions Oncology Inc, priceseries

Champions Oncology Inc. Daily Stock Analysis
Stock Information
Open
8.17
Close
7.96
High
8.24
Low
7.96
Previous Close
8.20
Daily Price Gain
-0.24
YTD High
12.80
YTD High Date
Jan 31, 2019
YTD Low
7.34
YTD Low Date
Apr 17, 2019
YTD Price Change
0.07
YTD Gain
0.89%
52 Week High
17.90
52 Week High Date
Oct 1, 2018
52 Week Low
5.80
52 Week Low Date
Jul 16, 2018
52 Week Price Change
1.86
52 Week Gain
30.49%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Dec 30. 2016
2.53
Jan 18. 2017
3.28
11 Trading Days
29.77%
Link
LONG
Jan 25. 2017
3.66
Feb 7. 2017
4.14
9 Trading Days
13.19%
Link
LONG
Jun 15. 2017
2.46
Jun 29. 2017
2.64
10 Trading Days
7.48%
Link
LONG
Jul 28. 2017
2.78
Aug 16. 2017
3.09
13 Trading Days
11.22%
Link
LONG
Nov 22. 2017
3.67
Nov 27. 2017
3.90
2 Trading Days
6.40%
Link
LONG
Apr 25. 2018
4.09
May 11. 2018
4.34
12 Trading Days
6.22%
Link
LONG
May 30. 2018
4.36
Jun 29. 2018
6.57
22 Trading Days
50.73%
Link
LONG
Jul 17. 2018
7.30
Jul 30. 2018
8.18
9 Trading Days
12.01%
Link
LONG
Sep 17. 2018
11.57
Sep 21. 2018
12.17
4 Trading Days
5.21%
Link
LONG
Jan 4. 2019
8.36
Jan 23. 2019
9.55
12 Trading Days
14.25%
Link
Company Information
Stock Symbol
CSBR
Exchange
NasdaqCM
Company URL
http://www.championsoncology.com
Company Phone
410-369-0365
CEO
Ronnie Morris
Headquarters
Maryland
Business Address
855 N. WOLFE STREET, SUITE 619, BALTIMORE, MD 21205
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0000771856
About

Champions Oncology, Inc. is engages in the development and sale of technology solutions and products to personalize the development and use of oncology drugs. It operates in the Personalized Oncology Solutions and Translational Oncology Solutions segments. The Personalized Oncology Solutions segment provides services to physicians and patients looking for information to help guide the development of a personalized treatment plans. The Translational Oncology Solutions segment provides services to pharmaceutical and biotechnology companies seeking personalized approaches to drug development that will lower the cost and increase the speed of developing new drugs and increasing the adoption of existing drugs. The company was founded by James M. Martell and David Sidransky on June 4, 1985 and is headquartered in Hackensack, NJ.

Description

Champions Oncology, Inc. develops and sells technology solutions and products to personalize the development and use of oncology drugs in the United States. Its Tumorgraft Technology Platform is an approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. The company, through its Tumorgraft Technology Platform, provides Personalized Oncology Solutions (POS) that assist physicians in developing personalized treatment options for cancer patients through tumor specific data obtained from drug panels and related personalized oncology services. It also offers POS products, including personalized tumor boards that are designed to provide access to oncologists with expertise in particular tumor types; and provides access to gene sequencing that analyzes the genetic makeup of patient's tumor for the purpose of identifying useful drugs. In addition, the company offers Translational Oncology Solutions (TOS), including a preclinical Tumorgraft platform to pharmaceutical and biotechnology companies that use vivo studies, which rely on implanting multiple tumors from TumorBank in mice and testing the therapy of interest on tumors. Further, it provides a bank of tumors that are acquired, collected, processed, validated, and stored for the use in TOS. The company markets its products through Internet, word of mouth, and a network of sales force. It serves patients, physicians, and drug development companies. The company was formerly known as Champions Biotechnology, Inc. and changed its name to Champions Oncology, Inc. in April 2011 to reflect its new focus on developing technologies to personalize the development and use of oncology drugs. Champions Oncology, Inc. is headquartered in Hackensack, New Jersey.